Ixaka

23 articles about Ixaka

• Ixaka Appoints Karen Miller as Chief Scientific Officer

  7/12/2022

  Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power of the body to cure disease, announces the appointment of Dr Karen Miller as Chief Scientific Officer.

• 

  Global Roundup: Italfarmaco Makes Progress against DMD, Clover Scores on Omicron

  6/30/2022

  Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.

• CELTIC-19 Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency

  3/8/2022

  Ixaka Ltd, an integrated cell and gene therapy company, announces that Advanced Therapy Medicinal Product classification has been granted by the European Medicines Agency for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy targeted nanoparticle product.

• Ixaka Expands Management Team with Multiple Appointments

  2/10/2022

  Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces the appointment of Nick Robbins-Cherry as Chief Financial Officer and board Director, and George O’Rourke as Vice President and General Manager of Ixaka France.

• Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

  9/8/2021

  Ixaka Ltd, an integrated cell and gene therapy company, announces positive interim results of its lead REX-001 drug candidate from a Phase 3 clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX-001 or placebo in patients diagnosed with chronic limb-threatening ischemia and diabetes.

• Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology

  6/29/2021

  Ixaka Ltd and SomaLogic announce a research collaboration to support the development of aptamer-based bispecific therapeutics.

• 

  Biopharmas Ink Strategic Partnerships for Research, Treating Major Diseases

  6/29/2021

  ​Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates. 

• Ixaka appoints Christian Hoyer Millar as a Non-Executive Director

  4/19/2021

  Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces that Christian Hoyer Millar has joined the Company’s Board as a Non-Executive Director.

• Rexgenero Appoints Sadia L’Baouch as Chief Manufacturing Officer

  12/7/2020

  Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia, announces the appointment of Sadia L’Baouch as Chief Manufacturing Officer, effective 4 January 2021.

• Rexgenero Announces Positive Outcome of Independent Data Monitoring Committee Meeting for Phase III Trial for Diabetic Patients with Critical Limb-Threatening Ischaemia

  10/26/2020

  REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients

• Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer

  7/2/2020

  Rexgenero announces that Dr Gilbert Wagener has joined the Company as Senior Vice President and Chief Medical Officer.

• Rexgenero Appoints Huw Jones as a Non-executive Director

  2/12/2020

  Rexgenero announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee.

• Rexgenero Appoints David Horn Solomon as Chairman

  2/10/2020

  Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia, announces that Dr. David Horn Solomon has been appointed to the role of Chairman, effective immediately.

• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.

• Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

  8/21/2019

  Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.

• First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava

  5/29/2019

  Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting

• Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service

  5/28/2019

  Enables new sites to participate in the European Phase III SALAMANDER trials

• Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

  4/24/2019

  At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona

• EMA Grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data

  1/30/2018

  The EMA certification paves the way for the MAA of its lead product REX-001, a novel cell therapy currently in a Phase III programme for the treatment of CLI. 

• Rexgenero Secures Innovate UK Grant

  1/23/2018

  The grant is a consortium between the Cell and Gene Therapy Catapult, TrakCel and Fisher Bioservices.